Amicus Therapeutics Hits New 52-Week High of $14.47

Amicus Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 14.47 on April 7, 2026. This achievement marks a notable increase from its 52-week low of USD 5.51, reflecting a robust performance over the past year. The stock has demonstrated a remarkable 43.98% increase in value, significantly outperforming the S&P 500, which has seen a gain of 30.71% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology sector, Amicus Therapeutics has a market capitalization of USD 4,512 million. Despite being a loss-making entity, the company maintains a debt-to-equity ratio of 0.59, indicating a manageable level of debt relative to its equity. The price-to-book ratio stands at 19.58, suggesting that the stock is trading at a premium compared to its book value. This recent price movement underscores the company's position within the market and highlights its performance metrics, which are essential for stakeholders monitoring the stock's trajectory.